Sorafenib in pretreated patients with advanced non-small lung cancer harbouring a K-ras mutation

被引：0
|
作者：
Dingemans, Anne-Marie C. [1 ]
van Wijk, Atie [2 ]
Hochstenbag, Monique [1 ]
Thunnissen, Erik [2 ]
Meulemans, Els [1 ]
Smit, Egbert F. [2 ]
机构：
[1] Maastricht Univ, Med Ctr, Maastricht, Netherlands
[2] VUMC, Amsterdam, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S414 / S415
页数：2
相关论文
共 50 条
  • [1] Sorafenib in Patients with Advanced Non-small Cell Lung Cancer that Harbor K-Ras Mutations A Brief Report
    Smit, Egbert F.
    Dingemans, Anne-Marie C.
    Thunnissen, Frederik B.
    Hochstenbach, Monique M.
    van Suylen, Robert-Jan
    Postmus, Pieter E.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : 719 - 720
  • [2] K-Ras Mutation among Colorectal and Non-Small Cell Lung Cancer Patients
    Zhou, Wei
    Brown, Holly
    Tice, Melissa
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S162 - S162
  • [3] A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with a K-Ras mutation
    Mellema, Wouter W.
    Dingemans, Anne-Marie C.
    Groen, Harry J. M.
    van Wijk, Atie
    Burgers, Sjaak
    Kunst, Peter W. A.
    Thunnissen, Frederik B.
    Heideman, Danielle A. M.
    Smit, Egbert F.
    CLINICAL CANCER RESEARCH, 2012, 18 (03)
  • [4] A Phase II Study of Sorafenib in Patients with Locally Advanced And/or Metastatic (stage IIIB or IV) Non-small Cell Lung Cancer (NSCLC) with a K-Ras Mutation
    Dingemans, A. M.
    Mellema, W. W.
    Groen, H. J. M.
    van Wijk, A.
    Burgers, S.
    Kunst, P. W. A.
    Thunnissen, F. B.
    Heideman, D. A. M.
    Smit, E. F.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 14 - 14
  • [5] K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer
    Cvetkovic, Gordana
    Plavec, Goran
    Tomic, Ilija
    Llic, Vesna
    Magic, Zvonko
    Tatomirovic, Zeljka
    Novkovic, Dobrivoje
    Milic, Rade
    Karlicic, Vukojica
    VOJNOSANITETSKI PREGLED, 2009, 66 (02) : 149 - 155
  • [6] Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
    Camps, C
    Sirera, R
    Bremnes, R
    Blasco, A
    Sancho, E
    Bayo, P
    Safont, MJ
    Sánchez, JJ
    Tarón, M
    Rosell, R
    LUNG CANCER, 2005, 50 (03) : 339 - 346
  • [7] Analysis of the prognostic role of plasmatic K-ras mutations in advanced non-small cell lung cancer (NSCLC) patients
    Sirera, R.
    Camps, C.
    Berrocal, A.
    Munoz-Navarro, M.
    Garcia-Gomez, R.
    Vinolas, N.
    Artal, A.
    Guillot, M.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] K-ras gene mutations in non-small cell lung cancer in Japanese
    Noda, N
    Matsuzoe, D
    Konno, T
    Kawahara, K
    Yamashita, Y
    Shirakusa, T
    ONCOLOGY REPORTS, 2001, 8 (04) : 889 - 892
  • [9] Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer
    Kim, DH
    Kim, JS
    Park, JH
    Lee, SK
    Ji, YI
    Kwon, YM
    Shim, YM
    Han, J
    Park, J
    CANCER RESEARCH, 2003, 63 (19) : 6206 - 6211
  • [10] K-ras mutation in sputum of patients with or without lung cancer
    Ronai, Z
    Yabubovskaya, MS
    Zhang, E
    Belitsky, GA
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1996, : 172 - 176
12345